Novo Nordisk subsupplier reinitiates Wegovy production

According to Novo Nordisk, a contract manufacturer filling the syringes for Novo’s obesity drug Wegovy has once again started its commercial production.
Photo: Pool/Reuters/Ritzau Scanpix
Photo: Pool/Reuters/Ritzau Scanpix
by marketwire, translated by daniel pedersen

In connection with Novo Nordisk’s first quarterly report Friday morning, the company has announced that the contract manufacturer in charge of filling Wegovy doses, an obesity treatment currently available in the US, has reinitiated its commercial production.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading